Exelixis’ Cabometyx R&D On Track Despite Pivotal Kidney Cancer Setback
The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.
You may also be interested in...
Activist Investor Demands Exelixis Cut R&D Spending And Learn From Peers
The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.
Part One Disappointment For BioXcel’s Igalmi In Pivotal Agitation Trial
The US firm’s drug for schizophrenia- and bipolar-related agitation Igalmi has failed part one of a pivotal trial in at-home patients, but the option for higher dosing in part two combined with placebo-like safety could offer hope.
Mirati’s Pivotal NSCLC Disappointment For Sitravatinib Combo ‘Unsurprising’
The US firm’s kinase inhibitor fell short of overall survival expectations in combination with a PD-1 inhibitor in an advanced lung cancer trial, but upcoming milestones for Krazati may be more of a concern.